Investigation of Immunovant, Inc.

Immunovant, Inc. (IMVT) Misled Shareholders About the Viability of its Drug Candidate IMVT-1401

According to a class action complaint filed on behalf of Immunovant shareholders, Health Sciences Acquisitions Corporation (HSAC) merged with Immunovant Sciences Ltd., a private biopharmaceutical company.  As a result of the merger, HSAC acquired all shares of Immunovant Sciences and Immonvant Sciences became a wholly owned subsidiary of HSAC.  HSAC then changed its name to Immunovant, Inc.  The Company is developing IMVT-1401 for the treatment of Graves’ ophthalmopathy and for the treatment of warm autoimmune hemolytic anemia.     

Between October 2, 2019 and February 2, 2021, defendants purportedly made false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Immunovant Sciences prior to the merger; (ii) HSAC ignored safety issues associated with Immunovant Science’s drug candidate IMVT-1401; and (iii) IMVT-1401 was less safe than the Company had led investors to believe, which foreseeably diminished its prospects for regulatory approval, commercial viability and profitability.

On February 2, 201, Immunovant issued a press release announcing “a voluntary pause of dosing in its original clinical trials for IMVT-1401,” and disclosed that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low density lipoproteins] levels in IMVT-1401-treated patients.”  On this news, Immunovant’s stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021.  The stock currently trades under $10.00 per share.


Immunovant, Inc. (IMVT) shareholders have legal options.  If you own shares of Immunovant, Inc. contact us to learn more about your rights.  All representation is on a contingency fee basis.  Shareholders pay no fees or expenses.

Have You Lost Money In This Company?

If you would like more information about your rights and potential remedies please send us a message.



Having information at your fingertips is easier than ever. Enroll in Robbins LLP’s free investment monitoring service, Stock Watch, for notifications of corporate misconduct impacting the value of your investments, advice on how to hold corporate officers and directors accountable for their misconduct, and to receive information about class action settlements.